

- Overall, this study observed no significant difference in the frequency CPK elevations in patients with or without concomitant statin therapy.
- The frequency of CPK elevation was not modified by the presence of other medications known to cause CPK elevations.
- Death was observed less frequently among statin recipients (9.4%) than non-recipients (17.2%).
- These findings have important implications for utilization of daptomycin since it may not be as toxic as previously perceived, regardless of whether used concomitantly with statin therapy.

This summary slide represents the opinions of the authors. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).